Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Aklief (trifarotene) is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.
• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Trifarotene 0.005% cream demonstrated effectiveness in treating both facial and truncal acne, with treatment success rates of 65.1% for facial acne (IGA rating) and 66.9% for truncal acne (PGA rating) in a 52-week phase III trial. The overall success rate, defined as success in both IGA and PGA in the same patient, was 57.9%.
• In the adolescent subgroup aged 12-17 with moderate acne, trifarotene showed good clinical efficacy for both facial and truncal acne, with notable improvements in Dermatology Quality of Life Index scores, where 52.8% of patients achieved a score of 0 or 1 after treatment compared to 22.6% at baseline.
• Trifarotene was generally well tolerated, with common adverse effects reported being pruritus, irritation, and sunburn. No severe safety concerns were highlighted in the reviewed studies.